Sorrento Therapeutics Stock Price, News & Analysis (NASDAQ:SRNE)

$6.40 0.35 (5.79 %)
(As of 01/22/2018 10:45 AM ET)
Previous Close$6.05
Today's Range$5.85 - $6.47
52-Week Range$1.50 - $6.47
Volume2.78 million shs
Average Volume2.65 million shs
Market Capitalization$586.98 million
P/E Ratio-15.24
Dividend YieldN/A
Beta1.04

About Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics logoSorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.

Receive SRNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:SRNE
CUSIPN/A
Phone+1-858-2034100

Debt

Debt-to-Equity Ratio0.18%
Current Ratio0.54%
Quick Ratio0.54%

Price-To-Earnings

Trailing P/E Ratio-15.2380952380952
Forward P/E Ratio-16.41
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.15 million
Price / Sales64.93
Cash FlowN/A
Price / CashN/A
Book Value$1.70 per share
Price / Book3.76

Profitability

Trailing EPS($0.42)
Net Income$-60,920,000.00
Net Margins-15.62%
Return on Equity-26.98%
Return on Assets-6.39%

Miscellaneous

Employees154
Outstanding Shares82,690,000

Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

How were Sorrento Therapeutics' earnings last quarter?

Sorrento Therapeutics Inc (NASDAQ:SRNE) issued its quarterly earnings data on Monday, November, 16th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter. The biopharmaceutical company earned $1.10 million during the quarter, compared to analyst estimates of $1.28 million. Sorrento Therapeutics had a negative net margin of 15.62% and a negative return on equity of 26.98%. View Sorrento Therapeutics' Earnings History.

Where is Sorrento Therapeutics' stock going? Where will Sorrento Therapeutics' stock price be in 2018?

5 equities research analysts have issued twelve-month price targets for Sorrento Therapeutics' stock. Their forecasts range from $7.00 to $30.00. On average, they expect Sorrento Therapeutics' share price to reach $15.00 in the next year. View Analyst Ratings for Sorrento Therapeutics.

Are investors shorting Sorrento Therapeutics?

Sorrento Therapeutics saw a increase in short interest in the month of December. As of December 29th, there was short interest totalling 2,558,145 shares, an increase of 31.0% from the December 15th total of 1,953,149 shares. Based on an average daily volume of 2,460,773 shares, the short-interest ratio is currently 1.0 days. Approximately 4.4% of the shares of the stock are short sold.

Who are some of Sorrento Therapeutics' key competitors?

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the folowing people:

  • William S. Marth, Independent Chairman of the Board (Age 61)
  • Henry H. Ji Ph.D., President, Chief Executive Officer, Director (Age 63)
  • Kevin Herde, Chief Financial Officer, Executive Vice President
  • Mike Royal M.D., Executive Vice President - Clinical and Regulatory Affairs (Age 61)
  • Miranda Jayne Toledano, Executive Vice President - Corporate Development
  • George Uy, Executive Vice President, Chief Commercial Officer (Age 59)
  • David Miao, Chief Technology Officer (Age 51)
  • Jaisim Shah, Director (Age 54)
  • Yue Wu Ph.D., Director
  • David H. Deming, Independent Director (Age 62)

Who owns Sorrento Therapeutics stock?

Sorrento Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (0.06%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde, Patrick Soon-Shiong and Yue Alexander Wu. View Institutional Ownership Trends for Sorrento Therapeutics.

Who bought Sorrento Therapeutics stock? Who is buying Sorrento Therapeutics stock?

Sorrento Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. Company insiders that have bought Sorrento Therapeutics stock in the last two years include Abg Management Ltd, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde and Yue Alexander Wu. View Insider Buying and Selling for Sorrento Therapeutics.

How do I buy Sorrento Therapeutics stock?

Shares of Sorrento Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sorrento Therapeutics' stock price today?

One share of Sorrento Therapeutics stock can currently be purchased for approximately $6.40.

How big of a company is Sorrento Therapeutics?

Sorrento Therapeutics has a market capitalization of $586.98 million and generates $8.15 million in revenue each year. The biopharmaceutical company earns $-60,920,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. Sorrento Therapeutics employs 154 workers across the globe.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 Directors Pl, SAN DIEGO, CA 92121-3836, United States. The biopharmaceutical company can be reached via phone at +1-858-2034100 or via email at [email protected]


MarketBeat Community Rating for Sorrento Therapeutics (SRNE)

Community Ranking:  4.0 out of 5 (star star star star)
Outperform Votes:  235 (Vote Outperform)
Underperform Votes:  56 (Vote Underperform)
Total Votes:  291
MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sorrento Therapeutics (NASDAQ:SRNE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $15.00$12.40$12.60$16.00
Price Target Upside: 145.90% upside439.13% upside609.86% upside742.11% upside

Sorrento Therapeutics (NASDAQ:SRNE) Consensus Price Target History

Price Target History for Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics (NASDAQ:SRNE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/19/2018OppenheimerReiterated RatingBuy$9.00HighView Rating Details
1/16/2018HC WainwrightReiterated RatingBuy$20.00 -> $30.00HighView Rating Details
8/3/2017Roth CapitalInitiated CoverageBuy$7.00HighView Rating Details
6/17/2017FBR & CoReiterated RatingBuyLowView Rating Details
5/22/2017Rodman & RenshawLower Price TargetBuy -> Buy$30.00 -> $20.00HighView Rating Details
8/12/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

Sorrento Therapeutics (NASDAQ:SRNE) Earnings History and Estimates Chart

Earnings by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics (NASDAQ SRNE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.20)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.33)($0.45)ViewN/AView Earnings Details
3/21/2017Q4 2016($0.27)($0.44)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.19)ViewN/AView Earnings Details
8/8/2016Q2 2016($0.17)($0.28)ViewN/AView Earnings Details
5/10/2016Q1 2016($0.37)($0.63)ViewN/AView Earnings Details
3/15/2016Q4 2015($0.63)ViewN/AView Earnings Details
11/16/2015Q315($0.03)$1.28 million$1.10 millionViewN/AView Earnings Details
8/7/2015Q2 2015($0.32)($0.30)ViewN/AView Earnings Details
5/5/2015Q1 2015($0.14)($0.29)ViewN/AView Earnings Details
3/13/2015Q4 2014($0.28)ViewN/AView Earnings Details
11/4/2014Q314($0.32)($0.27)$0.08 million$1.28 millionViewN/AView Earnings Details
8/6/2014($0.34)($0.33)$0.08 million$0.78 millionViewN/AView Earnings Details
5/14/2014($0.29)($0.44)$0.12 million$0.98 millionViewN/AView Earnings Details
4/1/2014Q4 2013($0.28)($0.35)ViewN/AView Earnings Details
11/14/2013Q3 2013($0.28)($0.23)ViewN/AView Earnings Details
8/13/2013Q2 2013($0.26)ViewN/AView Earnings Details
5/15/2013Q1 2013($0.01)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Sorrento Therapeutics (NASDAQ:SRNE) Earnings Estimates

2018 EPS Consensus Estimate: ($1.07)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.29)($0.29)($0.29)
Q2 20181($0.28)($0.28)($0.28)
Q3 20181($0.26)($0.26)($0.26)
Q4 20181($0.24)($0.24)($0.24)
Q1 20191($0.22)($0.22)($0.22)
Q2 20191($0.19)($0.19)($0.19)
Q3 20191($0.20)($0.20)($0.20)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Sorrento Therapeutics (NASDAQ:SRNE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Sorrento Therapeutics (NASDAQ SRNE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 11.87%
Insider Trades by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)
Institutional Ownership by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics (NASDAQ SRNE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/15/2017Henry JiInsiderBuy29,001$1.81$52,491.81139,776View SEC Filing  
6/15/2017Jaisim ShahDirectorBuy10,002$1.79$17,903.58112,633View SEC Filing  
4/19/2017Abg Management LtdMajor ShareholderBuy550,000$2.00$1,100,000.00View SEC Filing  
4/19/2017Henry JiCEOBuy100,000$2.00$200,000.00139,776View SEC Filing  
4/13/2017Abg Management LtdMajor ShareholderBuy2,500,000$2.00$5,000,000.00View SEC Filing  
2/22/2017Henry JiInsiderBuy2,000$5.60$11,200.0039,776View SEC Filing  
2/10/2017Henry JiInsiderBuy20,000$5.15$103,000.0037,776View SEC Filing  
2/3/2017Jerome B ZeldisInsiderBuy10,000$5.15$51,500.0010,000View SEC Filing  
2/3/2017Kevin HerdeVPBuy3,000$5.15$15,450.007,000View SEC Filing  
2/3/2017Yue Alexander WuDirectorBuy5,000$5.15$25,750.005,000View SEC Filing  
6/29/2016Patrick Soon-ShiongMajor ShareholderSell3,400$5.82$19,788.00720,174View SEC Filing  
6/23/2016Patrick Soon-ShiongMajor ShareholderSell6,901$5.85$40,370.85720,174View SEC Filing  
6/15/2016Patrick Soon-ShiongMajor ShareholderSell19,836$5.87$116,437.32720,174View SEC Filing  
6/14/2016Patrick Soon-ShiongMajor ShareholderSell53,764$6.14$330,110.96736,146View SEC Filing  
6/13/2016Patrick Soon-ShiongMajor ShareholderSell37,792$6.15$232,420.80736,146View SEC Filing  
3/7/2016Patrick Soon-ShiongMajor ShareholderSell100,000$6.19$619,000.00859,238View SEC Filing  
8/26/2015Henry JiCEOBuy500$0.95$475.00500View SEC Filing  
8/24/2015Henry JiCEOBuy8,888$12.84$114,121.9217,776View SEC Filing  
8/21/2015Henry JiCEOBuy8,888$13.08$116,255.0414,888View SEC Filing  
11/10/2014Henry JiCEOBuy5,999$4.83$28,975.17View SEC Filing  
11/7/2014Henry JiCEOBuy4,000$4.56$18,240.00View SEC Filing  
11/6/2014Henry JiCEOBuy3,000$4.53$13,590.00View SEC Filing  
12/5/2013Henry JiCEOBuy1,000$8.92$8,920.00View SEC Filing  
12/4/2013Henry JiCEOBuy1,000$8.54$8,540.00View SEC Filing  
11/25/2013Jaisim ShahDirectorBuy1,000$8.65$8,650.00View SEC Filing  
11/22/2013Henry JiCEOBuy1,000$8.47$8,470.00View SEC Filing  
11/22/2013Opko Health, Inc.Major ShareholderSell8,471$8.50$72,003.50View SEC Filing  
11/21/2013George UyInsiderBuy3,000$8.36$25,080.00View SEC Filing  
11/21/2013Opko Health, Inc.Major ShareholderSell4,269$8.53$36,414.57View SEC Filing  
11/20/2013Opko Health, Inc.Major ShareholderSell17,062$8.75$149,292.50View SEC Filing  
11/19/2013George UyInsiderBuy2,031$8.61$17,486.91View SEC Filing  
11/19/2013Henry JiCEOBuy2,000$8.59$17,180.00View SEC Filing  
11/19/2013Jaisim ShahDirectorBuy1,000$9.00$9,000.00View SEC Filing  
11/15/2013Opko Health, Inc.Major ShareholderSell2,710$8.75$23,712.50View SEC Filing  
11/14/2013Opko Health, Inc.Major ShareholderSell1,900$8.75$16,625.00View SEC Filing  
11/13/2013Opko Health, Inc.Major ShareholderSell13,457$8.75$117,748.75View SEC Filing  
11/8/2013Opko Health, Inc.Major ShareholderSell2,000$8.75$17,500.00View SEC Filing  
11/7/2013Opko Health, Inc.Major ShareholderSell120,380$9.03$1,087,031.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sorrento Therapeutics (NASDAQ SRNE) News Headlines

Source:
DateHeadline
Sorrento Therapeutics to Present at Noble Capital Markets Fourteenth Annual Investor Conference on 01/29/18 - GlobeNewswire (press release)Sorrento Therapeutics to Present at Noble Capital Markets' Fourteenth Annual Investor Conference on 01/29/18 - GlobeNewswire (press release)
www.globenewswire.com - January 22 at 8:05 AM
Sorrento Therapeutics to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference on 01/29/18Sorrento Therapeutics to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference on 01/29/18
finance.yahoo.com - January 22 at 8:05 AM
Oppenheimer Reaffirms "Buy" Rating for Sorrento Therapeutics (SRNE)Oppenheimer Reaffirms "Buy" Rating for Sorrento Therapeutics (SRNE)
www.americanbankingnews.com - January 19 at 8:04 PM
Critical Analysis: Sorrento Therapeutics (SRNE) & Achaogen (AKAO)Critical Analysis: Sorrento Therapeutics (SRNE) & Achaogen (AKAO)
www.americanbankingnews.com - January 18 at 9:36 PM
Sorrento Therapeutics (SRNE) Rating Reiterated by HC WainwrightSorrento Therapeutics (SRNE) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - January 16 at 8:08 AM
Sorrento Therapeutics Inc (SRNE) Short Interest UpdateSorrento Therapeutics Inc (SRNE) Short Interest Update
www.americanbankingnews.com - January 14 at 2:32 AM
Sorrento Therapeutics Inc (SRNE) Expected to Announce Quarterly Sales of $12.03 MillionSorrento Therapeutics Inc (SRNE) Expected to Announce Quarterly Sales of $12.03 Million
www.americanbankingnews.com - January 10 at 8:46 PM
Sorrento Therapeutics (SRNE) Lifted to "Buy" at BidaskClubSorrento Therapeutics (SRNE) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - January 6 at 3:36 PM
Sorrento Therapeutics (SRNE) Says it Will Present Potential Game ... - StreetInsider.comSorrento Therapeutics (SRNE) Says it Will Present Potential 'Game ... - StreetInsider.com
www.streetinsider.com - January 2 at 3:46 PM
Sorrento Therapeutics to Present Potential “Game-Changer” Non-Viral CAR-T Technology for Autologous and Allogeneic (off-the-shelf) CAR-T TherapiesSorrento Therapeutics to Present Potential “Game-Changer” Non-Viral CAR-T Technology for Autologous and Allogeneic (off-the-shelf) CAR-T Therapies
finance.yahoo.com - January 2 at 11:12 AM
Sorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018Sorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 11:09 AM
Sorrento Therapeutics Inc (SRNE) Receives Consensus Recommendation of "Buy" from BrokeragesSorrento Therapeutics Inc (SRNE) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 31 at 1:58 AM
ETFs with exposure to Sorrento Therapeutics, Inc. : December 27, 2017ETFs with exposure to Sorrento Therapeutics, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 1:26 PM
Sorrento Therapeutics (SRNE) Upgraded at BidaskClubSorrento Therapeutics (SRNE) Upgraded at BidaskClub
www.americanbankingnews.com - December 24 at 12:26 AM
SRNE Dec 2017 7.500 callSRNE Dec 2017 7.500 call
finance.yahoo.com - December 6 at 11:47 AM
$4.23 Million in Sales Expected for Sorrento Therapeutics Inc (SRNE) This Quarter$4.23 Million in Sales Expected for Sorrento Therapeutics Inc (SRNE) This Quarter
www.americanbankingnews.com - December 6 at 2:46 AM
Sorrento Therapeutics Inc (SRNE) Given Average Rating of "Buy" by BrokeragesSorrento Therapeutics Inc (SRNE) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 6 at 1:46 AM
-$0.23 EPS Expected for Sorrento Therapeutics, Inc. (SRNE) This Quarter-$0.23 EPS Expected for Sorrento Therapeutics, Inc. (SRNE) This Quarter
www.americanbankingnews.com - December 4 at 11:26 PM
Sorrento Therapeutics, Inc. (SRNE) Given a $6.00 Price Target by Oppenheimer Holdings, Inc. AnalystsSorrento Therapeutics, Inc. (SRNE) Given a $6.00 Price Target by Oppenheimer Holdings, Inc. Analysts
www.americanbankingnews.com - November 19 at 10:20 PM
ETFs with exposure to Sorrento Therapeutics, Inc. : November 17, 2017ETFs with exposure to Sorrento Therapeutics, Inc. : November 17, 2017
finance.yahoo.com - November 18 at 11:56 AM
Q1 2018 Earnings Forecast for Sorrento Therapeutics, Inc. Issued By Oppenheimer Holdings (SRNE)Q1 2018 Earnings Forecast for Sorrento Therapeutics, Inc. Issued By Oppenheimer Holdings (SRNE)
www.americanbankingnews.com - November 17 at 11:00 PM
Sorrento Therapeutics (SRNE) Subsidiary Files MAA For ZTlido - StreetInsider.comSorrento Therapeutics (SRNE) Subsidiary Files MAA For ZTlido - StreetInsider.com
www.streetinsider.com - November 15 at 11:16 AM
Sorrento Therapeutics (SRNE) Subsidiary Files MAA For ZTlidoSorrento Therapeutics (SRNE) Subsidiary Files MAA For ZTlido
www.streetinsider.com - November 15 at 11:16 AM
Scilex Pharmaceuticals, Sorrento Therapeutics Subsidiary, Files Marketing Authorization Application In The European Union For ZTlido™Scilex Pharmaceuticals, Sorrento Therapeutics' Subsidiary, Files Marketing Authorization Application In The European Union For ZTlido™
finance.yahoo.com - November 15 at 11:16 AM
Sorrento Therapeutics, Inc. (SRNE) Receives Average Rating of "Buy" from AnalystsSorrento Therapeutics, Inc. (SRNE) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 11 at 1:46 AM
Critical Survey: Sorrento Therapeutics (SRNE) & Its CompetitorsCritical Survey: Sorrento Therapeutics (SRNE) & Its Competitors
www.americanbankingnews.com - November 8 at 1:18 AM
Breakfast Technical Briefing on Biotech Stocks -- Cytori Therapeutics, Sorrento Therapeutics, Marinus Pharma, and NewLink GeneticsBreakfast Technical Briefing on Biotech Stocks -- Cytori Therapeutics, Sorrento Therapeutics, Marinus Pharma, and NewLink Genetics
www.prnewswire.com - November 7 at 11:02 AM
Sorrento Therapeutics (SRNE) & Its Rivals Critical AnalysisSorrento Therapeutics (SRNE) & Its Rivals Critical Analysis
www.americanbankingnews.com - November 7 at 10:58 AM
ETFs with exposure to Sorrento Therapeutics, Inc. : November 2, 2017ETFs with exposure to Sorrento Therapeutics, Inc. : November 2, 2017
finance.yahoo.com - November 4 at 5:06 PM
Sorrento Therapeutics (SRNE) versus Its Rivals Financial SurveySorrento Therapeutics (SRNE) versus Its Rivals Financial Survey
www.americanbankingnews.com - November 2 at 1:28 AM
Sorrento Therapeutics, Inc. (SRNE) Expected to Post Quarterly Sales of $4.23 MillionSorrento Therapeutics, Inc. (SRNE) Expected to Post Quarterly Sales of $4.23 Million
www.americanbankingnews.com - October 30 at 1:02 AM
Adgero Biopharmaceuticals Appoints John Liatos as Chief Financial OfficerAdgero Biopharmaceuticals Appoints John Liatos as Chief Financial Officer
finance.yahoo.com - October 25 at 11:11 AM
ETFs with exposure to Sorrento Therapeutics, Inc. : October 23, 2017ETFs with exposure to Sorrento Therapeutics, Inc. : October 23, 2017
finance.yahoo.com - October 24 at 10:27 AM
Sorrento Therapeutics, Inc. (SRNE) Given Average Rating of "Buy" by BrokeragesSorrento Therapeutics, Inc. (SRNE) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 17 at 2:52 AM
Sorrento Therapeutics, Inc. (SRNE) Sees Significant Decrease in Short InterestSorrento Therapeutics, Inc. (SRNE) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - October 15 at 2:20 AM
ETFs with exposure to Sorrento Therapeutics, Inc. : October 10, 2017ETFs with exposure to Sorrento Therapeutics, Inc. : October 10, 2017
finance.yahoo.com - October 11 at 8:04 AM
Head-To-Head Survey: Sorrento Therapeutics (SRNE) and Epizyme (EPZM)Head-To-Head Survey: Sorrento Therapeutics (SRNE) and Epizyme (EPZM)
www.americanbankingnews.com - October 11 at 6:28 AM
H.C. Wainwright Sees Over 1000% Upside for Sorrento Therapeutics (SRNE)H.C. Wainwright Sees Over 1000% Upside for Sorrento Therapeutics (SRNE)
finance.yahoo.com - October 6 at 12:46 PM
Sorrento Therapeutics, Inc. (SRNE) Stock Rating Reaffirmed by HC WainwrightSorrento Therapeutics, Inc. (SRNE) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - October 5 at 4:56 PM
Technical Insights on Biotech Stocks -- Cymabay Therapeutics, Cytori Therapeutics, CytRx, and Sorrento TherapeuticsTechnical Insights on Biotech Stocks -- Cymabay Therapeutics, Cytori Therapeutics, CytRx, and Sorrento Therapeutics
www.bizjournals.com - October 3 at 12:52 PM
Sorrento Therapeutics Appoints Mr. Dorman Followwill And Mr. Dave Lemus To The Board Of DirectorsSorrento Therapeutics Appoints Mr. Dorman Followwill And Mr. Dave Lemus To The Board Of Directors
www.thestreet.com - October 2 at 9:16 AM
Sorrento Therapeutics, Inc. (SRNE) Given Consensus Rating of "Buy" by BrokeragesSorrento Therapeutics, Inc. (SRNE) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 22 at 2:34 AM
Sorrento Therapeutics, Inc. To Present At Cantor Global Healthcare Conference (09/25/17 - 2:25 PM ET)Sorrento Therapeutics, Inc. To Present At Cantor Global Healthcare Conference (09/25/17 - 2:25 PM ET)
finance.yahoo.com - September 20 at 9:26 AM
Sorrento Therapeutics, Inc. (SRNE) Given Buy Rating at HC WainwrightSorrento Therapeutics, Inc. (SRNE) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - September 18 at 10:16 PM
FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido™; PDUFA Date Set For February 28, 2018FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido™; PDUFA Date Set For February 28, 2018
finance.yahoo.com - September 12 at 10:14 AM
Sorrento Therapeutics, Inc. To Present At 19th Rodman And Renshaw Global Investment Conference (09/11/17 - 17:30 ET)Sorrento Therapeutics, Inc. To Present At 19th Rodman And Renshaw Global Investment Conference (09/11/17 - 17:30 ET)
finance.yahoo.com - September 9 at 8:52 AM
ETFs with exposure to Sorrento Therapeutics, Inc. : September 1, 2017ETFs with exposure to Sorrento Therapeutics, Inc. : September 1, 2017
finance.yahoo.com - September 4 at 6:52 AM
ETFs with exposure to Sorrento Therapeutics, Inc. : September 1, 2017ETFs with exposure to Sorrento Therapeutics, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 9:07 AM
Sorrento Therapeutics (SRNE) Submits ZTlido NDASorrento Therapeutics (SRNE) Submits ZTlido NDA
www.streetinsider.com - August 31 at 10:24 AM
FY2017 Earnings Forecast for Sorrento Therapeutics, Inc. (SRNE) Issued By Oppenheimer HoldingsFY2017 Earnings Forecast for Sorrento Therapeutics, Inc. (SRNE) Issued By Oppenheimer Holdings
www.americanbankingnews.com - August 31 at 9:06 AM

SEC Filings

Sorrento Therapeutics (NASDAQ:SRNE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sorrento Therapeutics (NASDAQ:SRNE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sorrento Therapeutics (NASDAQ SRNE) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.